Reduced bone mineral density in Chinese children with phenylketonuria
-
Kundi Wang
,
Honglei Li
Abstract
Background:
Phenylketonuria (PKU) is an autosomal recessive metabolic disorder. Dietary control of classic PKU needs restriction of natural proteins. The diet results in unbalanced nutrition, which might affect the physical development of the patients. Our aim was to evaluate bone mineral density (BMD) in children with PKU.
Methods:
To investigate the BMD of children with PKU, 41 children with PKU and 64 healthy controls were recruited (all 3–4 years of age). Body weight and height, BMD, Phe blood levels, thyroid function, calcium, phosphorus, iron metabolism markers, and vitamin D3 were measured.
Results:
Body height and BMD of patients were lower than in controls. The BMD of controls was positively associated with age, body weight and height. In patients, BMD was positively associated with body weight. There was no correlation between Phe blood levels and BMD in patients. Blood levels of alkaline phosphatase were higher in patients compared to controls. Blood calcium levels were higher in 4-year-old patients, while the body weight was lower compared to controls. Thyroid function, iron metabolism markers, vitamin D3 levels and IGF-1 levels were normal.
Conclusions:
Reduced BMD was observed in children with phenylketonuria, but the exact reasons for this remain to be elucidated.
Acknowledgments
The authors acknowledge the invaluable participation of the children and their parents. We also thank Professor Shiping Zhao and Chief Pharmacist Gang Cui of China-Japan Friendship Hospital for their help in patient data management.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: The study was supported by the research fund of the China-Japan Friendship Hospital Grant no. 2010-MS-11.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417–27.10.1016/S0140-6736(10)60961-0Search in Google Scholar
2. van Spronsen FJ. Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol 2010;6:509–14.10.1038/nrendo.2010.125Search in Google Scholar PubMed
3. Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014;16:188–200.10.1038/gim.2013.157Search in Google Scholar PubMed
4. The Subspecialty Group of Endocinologic HaMD, The Society of Pediatrics, Chinese Medical Association. The diagnosis and treatment of high blood phenylalanine consensus. Chinese Journal of Pediatrics 2014;52:420–25.Search in Google Scholar
5. de Groot MJ, Hoeksma M, van Rijn M, Slart RH, van Spronsen FJ. Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients. Mol Genet Metab 2012;105:566–70.10.1016/j.ymgme.2012.01.006Search in Google Scholar PubMed
6. Koura HM, Abdallah Ismail N, Kamel AF, Ahmed AM, Saad-Hussein A, et al. A long-term study of bone mineral density in patients with phenylketonuria under diet therapy. Arch Med Sci 2011;7:493–500.10.5114/aoms.2011.23417Search in Google Scholar PubMed PubMed Central
7. Modan-Moses D, Vered I, Schwartz G, Anikster Y, Abraham S, et al. Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis 2007;30:202–8.10.1007/s10545-007-0462-9Search in Google Scholar PubMed
8. Solverson P, Murali SG, Litscher SJ, Blank RD, Ney DM. Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet. PLoS One 2012;7:e45165.10.1371/journal.pone.0045165Search in Google Scholar PubMed PubMed Central
9. Barat P, Barthe N, Redonnet-Vernhet I, Parrot F. The impact of the control of serum phenylalanine levels on osteopenia in patients with phenylketonuria. Eur J Pediatr 2002;161:687–8.10.1007/s00431-002-1091-9Search in Google Scholar PubMed
10. Mendes AB, Martins FF, Cruz WM, da Silva LE, Abadesso CB, et al. Bone development in children and adolescents with PKU. J Inherit Metab Dis 2012;35:425–30.10.1007/s10545-011-9412-7Search in Google Scholar PubMed
11. Perez-Duenas B, Cambra FJ, Vilaseca MA, Lambruschini N, Campistol J, et al. New approach to osteopenia in phenylketonuric patients. Acta Paediatr 2002;91:899–904.10.1111/j.1651-2227.2002.tb02852.xSearch in Google Scholar
12. Nih Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. J Am Med Assoc 2001;285:785–95.10.1001/jama.285.6.785Search in Google Scholar PubMed
13. Stojiljkovic M, Klaassen K, Djordjevic M, Sarajlija A, Kecman B, et al. Tetrahydrobiopterin deficiency among Serbian patients presenting with hyperphenylalaninemia. J Pediatr Endocrinol Metab 2015;28:477–80.10.1515/jpem-2014-0297Search in Google Scholar PubMed
14. Prochazkova D, Jarkovsky J, Hankova Z, Konecna P, Benakova H, et al. Long-term treatment for hyperphenylalaninemia and phenylketonuria: a risk for nutritional vitamin B12 deficiency? J Pediatr Endocrinol Metab 2015;28:1327–32.10.1515/jpem-2014-0489Search in Google Scholar PubMed
15. Zhen-Wang B, Cheng-Ye J. Secular growth changes in body height and weight in children and adolescents in Shandong, China between 1939 and 2000. Ann Hum Biol 2005;32:650–65.10.1080/03014460500154418Search in Google Scholar PubMed
16. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033–46.10.1007/s00198-007-0343-ySearch in Google Scholar PubMed
17. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1–129.Search in Google Scholar
18. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368–81.10.1007/BF01622200Search in Google Scholar PubMed
19. Britto JM, Fenton AJ, Holloway WR, Nicholson GC. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994;134:169–76.10.1210/endo.134.1.8275930Search in Google Scholar PubMed
20. Holmes SJ, Shalet SM. Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Horm Res 1996;45:86–93.10.1159/000184765Search in Google Scholar PubMed
21. Locatelli V, Bianchi VE. Effect of GH/IGF-1 on bone metabolism and osteoporsosis. Int J Endocrinol 2014;2014:235060.10.1155/2014/235060Search in Google Scholar PubMed PubMed Central
22. Bell TD, Demay MB, Burnett-Bowie SA. The biology and pathology of vitamin D control in bone. J Cell Biochem 2010;111:7–13.10.1002/jcb.22661Search in Google Scholar PubMed PubMed Central
23. Clemens TL. Vitamin B12 deficiency and bone health. N Engl J Med 2014;371:963–4.10.1056/NEJMcibr1407247Search in Google Scholar PubMed
24. Anh DJ, Dimai HP, Hall SL, Farley JR. Skeletal alkaline phosphatase activity is primarily released from human osteoblasts in an insoluble form, and the net release is inhibited by calcium and skeletal growth factors. Calcif Tissue Int 1998;62:332–40.10.1007/s002239900441Search in Google Scholar PubMed
25. Turan S, Topcu B, Gokce I, Guran T, Atay Z, et al. Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets. J Clin Res Pediatr Endocrinol 2011;3:7–11.10.4274/jcrpe.v3i1.02Search in Google Scholar PubMed PubMed Central
26. Otero JL, Gonzalez-Peralta RP, Andres JM, Jolley CD, Novak DA, et al. Elevated alkaline phosphatase in children: an algorithm to determine when a “Wait and See” approach is optimal. Clin Med Insights Pediatr 2011;5:15–8.10.4137/CMPed.S6872Search in Google Scholar PubMed PubMed Central
27. Miras A, Boveda MD, Leis MR, Mera A, Aldamiz-Echevarria L, et al. Risk factors for developing mineral bone disease in phenylketonuric patients. Mol Genet Metab 2013;108:149–54.10.1016/j.ymgme.2012.12.008Search in Google Scholar PubMed
28. Nagasaka H, Tsukahara H, Takatani T, Sanayama Y, Takayanagi M, et al. Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening. J Bone Miner Metab 2011;29: 737–43.10.1007/s00774-011-0276-6Search in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review
- Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials
- Original Articles
- Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus
- Does body fat percentage predict post-exercise heart rate response in non-obese children and adolescents?
- The relationship between insulin resistance and endothelial dysfunction in obese adolescents
- Neck circumference is similarly predicting for impairment of glucose tolerance as classic anthropometric parameters among healthy and obese children and adolescents
- Reduced bone mineral density in Chinese children with phenylketonuria
- Assessment of stress levels in girls with central precocious puberty before and during long-acting gonadotropin-releasing hormone agonist treatment: a pilot study
- Association study of LIN28B in girls with precocious puberty
- Molecular genetics of growth hormone deficient children: correlation with auxology and response to first year of growth hormone therapy
- Evaluation of factors associated with elevated newborn 17-hydroxyprogesterone levels
- Evaluation of endocrine and metabolic dysfunctions after hematopoietic stem cell transplantation in children: a study from Turkey
- Case Reports
- Opioid-induced hyponatremia in a patient with central diabetes insipidus: independence from ADH
- Deoxyguanosine kinase deficiency: a report of four patients
- Fructose-1,6-bisphosphatase deficiency caused by a novel homozygous Alu element insertion in the FBP1 gene and delayed diagnosis
Articles in the same Issue
- Frontmatter
- Review
- Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials
- Original Articles
- Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus
- Does body fat percentage predict post-exercise heart rate response in non-obese children and adolescents?
- The relationship between insulin resistance and endothelial dysfunction in obese adolescents
- Neck circumference is similarly predicting for impairment of glucose tolerance as classic anthropometric parameters among healthy and obese children and adolescents
- Reduced bone mineral density in Chinese children with phenylketonuria
- Assessment of stress levels in girls with central precocious puberty before and during long-acting gonadotropin-releasing hormone agonist treatment: a pilot study
- Association study of LIN28B in girls with precocious puberty
- Molecular genetics of growth hormone deficient children: correlation with auxology and response to first year of growth hormone therapy
- Evaluation of factors associated with elevated newborn 17-hydroxyprogesterone levels
- Evaluation of endocrine and metabolic dysfunctions after hematopoietic stem cell transplantation in children: a study from Turkey
- Case Reports
- Opioid-induced hyponatremia in a patient with central diabetes insipidus: independence from ADH
- Deoxyguanosine kinase deficiency: a report of four patients
- Fructose-1,6-bisphosphatase deficiency caused by a novel homozygous Alu element insertion in the FBP1 gene and delayed diagnosis
